The United Laboratories International Holdings Limited
聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 3933)

FDA APPROVAL OF IND FOR UBT251 INJECTION ON INDICATION OF CKD

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors (the "Board") of the Company is pleased to announce that UBT251 Injection, a Class 1 innovative drug self-developed by The United Bio-Technology (Hengqin) Co., Ltd., a wholly-owned subsidiary of the Company, has been approved for phase II clinical trial on indication of chronic kidney disease ("CKD") by the U.S. Food and Drug Administration ("FDA"). Previously, the indication of CKD has been approved for clinical trial by China National Medical Products Administration on 20 January 2025.

According to the preclinical obesity/diabetic nephropathy pharmacodynamic model, UBT251 demonstrated significantly superior overall improvement effects on renal urinary albumin and other related renal injury markers and histopathology than Semaglutide. It is expected to provide new options for the treatment of metabolism-related chronic kidney disease, thereby better fulfilling clinical therapeutic demands.

UBT251 is a long-acting triple agonist of GLP-1 (glucagon-like peptide-1) /GIP (glucose-dependent insulinotropic polypeptide) /GCG (glucagon). The Company is the first enterprise in China and the second enterprise in the world to be approved for the clinical trials of a long-acting triple agonist of GLP-1/GIP/GCG prepared by chemical synthetic polypeptide. Currently, indications of T2DM, overweight or obesity and CKD have obtained approval for clinical trials in both China and the U.S. and have entered clinical trials in China.

In the future, the Company will continue to commit itself to the research and development of new products, and focus on enhancing its competitiveness and creativity in the biopharmaceutical industry, with a view of creating more benefits for the Company and its shareholders.

By Order of the Board
The United Laboratories International Holdings Limited
Tsoi Hoi Shan
Chairman

Hong Kong, 3 March 2025

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.